Laboratory Developed Tests Market Size & Growth Forecast 2026–2035, By Segments (Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Laboratory Developed Tests Market size was worth USD 13.87 Billion in 2025 and is expected to grow at a 7.1% CAGR between 2026 and 2035, crossing USD 27.54 Billion by 2035. The industry revenue for 2026 is calculated at USD 14.73 billion.

• Base Year Value (2025): USD 13.87 Billion
• CAGR (2026-2035): 7.1%
• Forecast Year Value (2035): USD 27.54 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Laboratory Developed Tests Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America captured 39.78% of the market in 2025 due to its advanced laboratory infrastructure, strong molecular testing capabilities, and widespread use of specialized diagnostics across clinical care settings.
  • Asia Pacific is expected to grow at an 8.02% CAGR as healthcare systems expand laboratory capabilities, increase molecular testing adoption, and improve access to specialized diagnostic services.

• Segment Momentum:

  • Oncology held a 23.92% share in 2025 because laboratories rely on highly tailored testing for cancer detection, characterization, and treatment monitoring, sustaining strong demand for specialized diagnostic solutions.
  • Immunoassays are the fastest-growing technology segment as laboratories adopt scalable, workflow-friendly testing methods that support broad biomarker detection with greater operational flexibility.

• Market Expansion Drivers:

  • Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand.
  • Expansion of personalized medicine and precision oncology driving advanced test utilization.
  • AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency.

• Leading Market Participants:

  Top companies in the laboratory developed tests market include Illumina, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics Incorporated (United States), Abbott Laboratories (United States), Siemens Healthineers AG (Germany), QIAGEN N.V. (Germany), Guardant Health, Inc. (United States), NeoGenomics, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Exact Sciences Corporation (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 13.87 Billion
  • Projected Market Size: USD 27.54 Billion by 2035
  • Growth Forecasts: 7.1% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Molecular Diagnostics (Technology) | Oncology (Application)
  • Emerging Opportunity Segment: Immunoassays (Technology) | Nutritional & Metabolic Disease (Application)

Market Growth Drivers and Industry Trends

Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand

Growing incidence of cancer and inherited disorders is pushing clinicians to seek faster, more tailored diagnostic answers than standardized assays often provide, driving demand for the laboratory developed tests market. Hospitals, oncology centers, and specialty reference labs increasingly rely on laboratory developed tests to detect rare mutations, stratify disease subtypes, and support treatment selection when commercially available kits do not cover the needed biomarkers or lack sufficient flexibility. This dynamic is driving market development as laboratories invest in disease-specific panels, expand molecular testing menus, and integrate more complex workflows that respond to rising volumes of patients requiring earlier and more precise diagnostic assessment.

Expansion of personalized medicine and precision oncology driving advanced test utilization

As treatment decisions become more closely tied to individual biomarker profiles, the laboratory developed tests market is gaining momentum from the need for assays that can match specific clinical questions, sample types, and therapeutic pathways. Precision oncology in particular is increasing market penetration for multi-gene panels, companion-style testing approaches, and longitudinal monitoring assays because laboratories need the ability to update targets quickly as new therapies and resistance markers emerge. That flexibility is influencing market adoption among providers and health systems that prefer laboratory developed tests when they need clinically actionable results beyond the scope of fixed-format diagnostics.

AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency

AI-supported sequencing analysis and laboratory automation are reshaping operating economics in the laboratory developed tests market by reducing interpretation bottlenecks, improving workflow consistency, and enabling higher sample throughput without proportional increases in manual labor. In practice, this allows molecular laboratories to process more complex datasets, shorten turnaround times, and scale specialized testing services that were previously constrained by staffing intensity and analytical complexity. The result is stronger market expansion as providers become more willing to adopt advanced laboratory developed tests when delivery becomes faster, more reproducible, and better aligned with routine clinical decision timelines.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising cancer and genetic disorder burden accelerating laboratory developed diagnostic demand	2.20%	High	North America, Europe	High	Near Term
Expansion of personalized medicine and precision oncology driving advanced test utilization	2.00%	High	North America, Europe, Asia Pacific	High	Mid Term
AI-enabled genomic sequencing and lab automation improving diagnostic throughput efficiency	1.60%	Moderate	North America, Asia Pacific	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 39.78% share of the laboratory developed tests market in 2025, bolstered by the region’s established clinical laboratory infrastructure, broad availability of advanced molecular and genetic testing capabilities, and strong integration of specialized diagnostics into routine care pathways. Demand remains concentrated in settings where hospitals, reference labs, and academic medical centers can rapidly develop and validate tests for oncology, infectious disease, rare disease, and precision medicine applications. This operating environment helps sustain regional leadership because laboratories have the technical depth, installed instrumentation, and clinician access needed to move from assay development to regular clinical use efficiently.

Asia Pacific is projected to expand at an 8.02% CAGR over the forecast period in the laboratory developed tests market, driven by rising adoption of advanced diagnostics across large patient populations and the ongoing buildout of laboratory capabilities in major healthcare systems. Growth is accelerating as providers increasingly use locally developed assays to address unmet testing needs, improve turnaround times, and broaden access to specialized diagnostics beyond top-tier urban centers. The region’s momentum is also reinforced by expanding use of molecular testing in disease detection and treatment selection, which is translating into stronger utilization of laboratory-developed offerings in day-to-day clinical practice.

Key Country Insights

United States

Precision Diagnostics Expansion

The U.S. laboratory developed tests market continues evolving through increasing demand for personalized medicine, molecular diagnostics, and specialized clinical testing. Laboratories in the U.S. invest in advanced assay development, automation, and data analytics to improve diagnostic accuracy and efficiency.

Japan

Clinical Testing Innovation

Japan prioritizes laboratory developed tests that enhance diagnostic precision and support individualized treatment decisions. Healthcare providers in Japan increasingly adopt advanced molecular technologies and automated laboratory workflows to improve testing efficiency and clinical utility.

South Korea

Molecular Testing Capability

South Korea is expanding laboratory developed tests through investments in advanced clinical laboratories and biotechnology innovation. Organizations strengthen genomic testing capabilities and specialized diagnostic services to support precision medicine across multiple therapeutic areas.

Germany

Quality Diagnostic Standards

Germany emphasizes laboratory developed tests that support precision diagnostics while maintaining rigorous analytical validation and quality requirements. German laboratories continue expanding advanced molecular testing capabilities across oncology, infectious diseases, and genetic diagnostics.

France

Specialized Diagnostic Services

France supports laboratory developed tests through collaboration between hospital laboratories, research institutions, and diagnostic developers. French laboratories continue refining specialized assays that address complex clinical conditions while supporting broader adoption of precision healthcare.

Italy

Laboratory Capacity Enhancement

Italy is strengthening laboratory developed tests by modernizing diagnostic infrastructure and expanding access to advanced molecular testing. Clinical laboratories in Italy emphasize standardized workflows, improved analytical performance, and specialized testing services for complex disease management.

Segment Leadership and Growth Trends

  Technology Segment Analysis: Molecular Diagnostics (Largest Segment) vs Immunoassays (Fastest-Growing Segment)

Molecular Diagnostics held a 27.79% share of the laboratory developed tests market in 2025, making it the leading technology segment. Its position is sustained by the practical role these tests play in detecting genetic, infectious, and disease-specific biomarkers with high analytical relevance for clinical decision-making. In the laboratory developed tests market, molecular diagnostics remains widely used because laboratories rely on it when precision, customization, and the ability to support complex case stratification are central to test design and adoption.

Immunoassays are emerging as the fastest-growing technology segment in the laboratory developed tests market as laboratories seek scalable testing approaches that can support broad clinical use with efficient workflow integration. Their momentum is tied to expanding demand for targeted protein and biomarker detection across routine and specialized settings, where turnaround needs and operational adaptability matter. Compared with more technically intensive alternatives, immunoassays are seeing wider adoption because they fit more readily into evolving lab requirements for accessible, application-flexible test development.

Application Segment Analysis: Oncology (Largest Segment) vs Nutritional & Metabolic Disease (Fastest-Growing Segment)

In 2025, Oncology accounted for a 23.92% share of the laboratory developed tests market, securing its place as the largest application segment. This leadership reflects the sustained need for highly tailored testing in cancer detection, characterization, and treatment monitoring, where laboratory developed tests are often used to address clinically specific biomarker requirements. The oncology segment continues to lead the laboratory developed tests market because disease complexity and the need for individualized diagnostic insight keep demand concentrated in this application area.

Nutritional & Metabolic Disease is the fastest-growing application segment in the laboratory developed tests market, backed by rising attention to condition-specific assessment that often requires more customized testing than standardized panels can provide. Growth is being encouraged by the practical need to evaluate diverse metabolic markers and nutritional imbalances with greater specificity across varied patient profiles. Relative to more established applications, this segment is gaining momentum as laboratories expand into areas where personalized assessment and flexible assay development are becoming more relevant to clinical practice.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Technology	Immunoassays, Hematology & Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy, Others	Molecular Diagnostics	Immunoassays
Application	Oncology, Genetic Disorders/Inherited Disease, Infectious & Parasitic Diseases, Immunology, Endocrine, Nutritional & Metabolic Disease, Cardiology, Mental/Behavioral Disorder, Pediatrics-specific Testing, Hematology/General Blood Testing, Bodily Fluid Analysis, Toxicology, Others	Oncology	Nutritional & Metabolic Disease

Competitive Landscape and Market Positioning

Leading companies in the laboratory developed tests market:

1. Illumina Inc. (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. Quest Diagnostics Incorporated (United States)

4. Abbott Laboratories (United States)

5. Siemens Healthineers AG (Germany)

6. QIAGEN N.V. (Germany)

7. Guardant Health Inc. (United States)

8. NeoGenomics Inc. (United States)

9. Thermo Fisher Scientific Inc. (United States)

10. Exact Sciences Corporation (United States)

The laboratory developed tests market is expanding due to increasing demand for personalized diagnostics and advanced clinical testing. Innovation in testing methodologies is improving diagnostic accuracy. The laboratory developed tests market is also influenced by regulatory frameworks guiding test validation and deployment.

Industry Development/News

Company Name	Date	Key Development
Plus Therapeutics	Aug-25	Plus Therapeutics secured College of American Pathologists (CAP) accreditation for its CNSide Diagnostics clinical laboratory. This milestone, which complements existing CLIA certification, enhances the firm’s quality assurance framework and supports the commercial rollout of its CNSide cerebrospinal fluid assay platform within the specialized central nervous system diagnostic testing market.
PrecisionLife & Ovation.io	Aug-25	PrecisionLife and Ovation.io announced a collaboration to develop laboratory-developed and direct-to-consumer genetic tests tailored to predict patient responses to GLP-1 therapies. This initiative underscores the increasing convergence of precision medicine and predictive diagnostics, aiming to optimize therapeutic matching and improve clinical outcomes through data-driven genomic testing.
Becton Dickinson	Jul-25	Becton Dickinson expanded its BD MAX diagnostic platform menu in Europe by integrating two IVDR-certified Viasure assays. This enhancement strengthens the company’s molecular diagnostics portfolio under stringent European regulatory standards, promoting greater clinical adoption of automated, high-throughput laboratory testing solutions for infectious disease management.
Roche	Jul-25	Roche launched updated cobas 6800/8800 version 2.0 systems and associated software following recent regulatory clearance. These upgrades significantly improve high-throughput molecular testing performance and workflow efficiency, reinforcing the company’s competitive position in providing automated laboratory infrastructure for infectious disease and clinical diagnostic applications.
Pictor	Jul-25	Pictor established its U.S. headquarters in California, a strategic move to accelerate the commercialization of its multiplex proteomics diagnostic platform. The expansion increases the availability of the company’s high-performance testing technology in the North American market and strengthens its operational footprint within the life sciences diagnostics ecosystem.
LabGenomics USA	Jun-25	LabGenomics USA expanded its U.S. clinical diagnostics network through the acquisition of Integrated Molecular Diagnostics laboratories. By increasing its portfolio to four CLIA-certified facilities, the company has significantly bolstered its laboratory testing capacity and enhanced its ability to scale molecular diagnostic services across the domestic clinical market.